OS Therapies Granted End Of Phase 2 Meeting By Us FDA For OST-HER2 Program In The Prevention Or Delay Of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

OS Therapies Inc OSTX:

• OS THERAPIES GRANTED END OF PHASE 2 MEETING BY US FDA FOR OST-HER2 PROGRAM IN THE PREVENTION OR DELAY OF RECURRENT, FULLY RESECTED, PULMONARY METASTATIC OSTEOSARCOMA

• OS THERAPIES INC - MEETING EXPECTED TO OCCUR IN Q3 2025

• OS THERAPIES INC - TO SEEK ROLLING REVIEW FOR BLA SUBMISSION

• OS THERAPIES INC - COMPANY ELIGIBLE FOR PRIORITY REVIEW VOUCHER IF APPROVED BEFORE SEPT 30, 2026